- Home
- GENK vs ATHA Comparison
GENK vs ATHA Comparison
Compare GENK & ATHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GENK
- ATHA
- Stock Information
- Founded
- GENK 2011
- ATHA 2011
- Country
- GENK United States
- ATHA United States
- Employees
- GENK N/A
- ATHA N/A
- Industry
- GENK Restaurants
- ATHA Medicinal Chemicals and Botanical Products
- Sector
- GENK Consumer Discretionary
- ATHA Health Care
- Exchange
- GENK Nasdaq
- ATHA Nasdaq
- Market Cap
- GENK 23.6M
- ATHA 21.0M
- IPO Year
- GENK 2023
- ATHA 2020
- Fundamental
- Price
- GENK $4.21
- ATHA $0.26
- Analyst Decision
- GENK Strong Buy
- ATHA Buy
- Analyst Count
- GENK 3
- ATHA 4
- Target Price
- GENK $12.17
- ATHA $11.25
- AVG Volume (30 Days)
- GENK 46.1K
- ATHA 214.5K
- Earning Date
- GENK 05-13-2025
- ATHA 05-09-2025
- Dividend Yield
- GENK N/A
- ATHA N/A
- EPS Growth
- GENK N/A
- ATHA N/A
- EPS
- GENK N/A
- ATHA N/A
- Revenue
- GENK $214,957,000.00
- ATHA N/A
- Revenue This Year
- GENK $20.48
- ATHA N/A
- Revenue Next Year
- GENK $21.64
- ATHA N/A
- P/E Ratio
- GENK N/A
- ATHA N/A
- Revenue Growth
- GENK 14.40
- ATHA N/A
- 52 Week Low
- GENK $3.99
- ATHA $0.22
- 52 Week High
- GENK $13.12
- ATHA $3.67
- Technical
- Relative Strength Index (RSI)
- GENK 41.04
- ATHA 45.40
- Support Level
- GENK $4.30
- ATHA $0.23
- Resistance Level
- GENK $5.26
- ATHA $0.30
- Average True Range (ATR)
- GENK 0.31
- ATHA 0.03
- MACD
- GENK 0.07
- ATHA 0.00
- Stochastic Oscillator
- GENK 25.38
- ATHA 37.12
About GENK GEN Restaurant Group Inc.
GEN Restaurant Group Inc operates an Asian casual dining restaurant chain, offering an extensive menu of traditional Korean and Korean-American food, including high-quality meats, poultry, seafood, and mixed vegetables. It operates 43 Gen Korean BBQ restaurants in the United States.
About ATHA Athira Pharma Inc.
Athira Pharma Inc is a late clinical-stage biopharmaceutical company focused on developing small molecules engineered to restore neuronal health and slow neurodegeneration. Its pipeline candidates are; Fosgonimeton (ATH-1017) a subcutaneously administered, small molecule positive modulator of the HGF/MET system for CNS disorders, ATH-1020 is a novel small molecule compound designed to be an orally available once-daily treatment, to enhance the HGF/MET system. ATH-1105 is a novel small molecule compound designed to be an orally available once-daily treatment, to enhance the HGF/MET system, and several other compounds in preclinical discovery and development for neurodegenerative diseases, including ATH-1018 and ATH-1019.